THERAPY

作品数：3169被引量：9979H指数：32
导出分析报告
相关领域：医药卫生更多>>
相关作者：王飘王祖承钱铭怡李太生贾春生更多>>
相关机构：首都医科大学第二军医大学复旦大学华中科技大学更多>>
相关期刊：更多>>
相关基金：国家自然科学基金国家重点基础研究发展计划中国博士后科学基金广东省自然科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
选择条件：
  • 期刊=Chinese Medical Journalx
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
An assessment model for efficacy of autologous CD19 chimeric antigen receptor T-cell therapy and relapse or refractory diffuse large B-cell lymphoma risk
《Chinese Medical Journal》2025年第1期108-110,共3页Bin Xue Yifan Liu Min Zhang Gangfeng Xiao Xiu Luo Lili Zhou Shiguang Ye Yan Lu Wenbin Qian Li Wang Ping Li Aibin Liang 
supported by grants from the National Key R&D Program of China(No.2021YFA1100800);National Natural Science Foundation of China(Nos.81830004 and 82070168);Translational Research Grant of NCRCH(No.2020ZKZC04);Shanghai Municipal Health Commission(No.2020CXJQ02);Cultivation project of National Natural Science Foundation of Shanghai Tongji Hospital(No.GJPY2332).
To the Editor:Autologous CD19 chimeric antigen receptor(CAR)T-cell therapy has emerged as a crucial treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma(r/r DLBCL).[1]While CAR-T-cel...
关键词：therapeutic efficacy chimeric antigen REFRACTORY predictive model Chimeric Antigen Receptor T cell therapy diffuse large B cell lymphoma 
Chimeric antigen receptor T cells targeting CD312 as a therapy for acute myeloid leukemia
《Chinese Medical Journal》2025年第1期114-116,共3页Danni Xie Bing Wang Xue Bai Xin Jin Wenyi Lu Meng Zhang Yi Zhang Xinping Cao Mingfeng Zhao 
supported by grants from the General Project of the National Natural Science Foundation of China(No.81970180);the Science and Technology Project of Tianjin Municipal Health Committee(No.TJWJ2022QN030);the Key Projects of Tianjin Applied Basic Research and Multi-Investment Fund(No.21JCZDJC01240);the Science and Technology Project of Tianjin Municipal Health Committee(No.TJWJ2022XK018);the Tianjin Key Medical Discipline(Specialty)Construction Project(No.TJYXZDXK-056B);the Tianjin Municipal Natural Science Foundation(No.22JCQNJC00820);the Tianjin Health Research Project(No.TJWJ2023QN027);the Tianjin Health Bureau Project(No.ZC20074);the Tianjin Key Medical Discipline(Specialty)Construction Project(No.TJWJ2023XK010).
To the Editor:Chimeric antigen receptor(CAR)-T-cell therapy has made considerable breakthroughs in the treatment of lymphoma and myeloma,but the lack of suitable or specific targets for acute myelocytic leukemia(AML)h...
关键词：CAR T Cell Therapy Hematopoietic Stem Cells Target Antigen hematopoietic stem cells hscs making Acute Myeloid Leukemia Chimeric Antigen Receptor T Cells 
Granulocyte colony-stimulating factor in neutropenia management after CAR-T cell therapy:A safety and efficacy evaluation in refractory/relapsed B-cell acute lymphoblastic leukemia
《Chinese Medical Journal》2025年第1期111-113,共3页Xinping Cao Meng Zhang Ruiting Guo Xiaomei Zhang Rui Sun Xia Xiao Xue Bai Cuicui Lyu Yedi Pu Juanxia Meng Huan Zhang Haibo Zhu Pengjiang Liu Zhao Wang Yu Zhang Wenyi Lu Hairong Lyu Mingfeng Zhao 
supported by grants from the General Project of the National Natural Science Foundation of China(No.81970180);the Science and Technology Project of Tianjin Municipal Health Committee(No.TJWJ2022QN030);the Key projects of Tianjin Applied Basic Research and Multi-Investment Fund(No.21JCZDJC01240);the Science and Technology Project of Tianjin Municipal Health Committee(No.TJWJ2022XK018);Tianjin Key Medical Discipline(Specialty)Construction Project(No.TJYXZDXK-056B);Tianjin Municipal Natural Science Foundation(No.22JCQNJC00820);Tianjin Health Research Project(No.TJWJ2023QN027);Tianjin Health Bureau Project(No.ZC20074);Tianjin Key Medical Discipline(Specialty)Construction Project(No.TJWJ2023XK010);Henan Provincial Youth and Middle-aged Health Science and Technology Talents Excellent Youth Program(No.20230273).
To the Editor:After chimeric antigen receptor T(CAR-T)cell therapy,over 90%of patients experience either mild or severe cytopenia,with the prevalence of Grades 3–4 neutropenia ranging from 53%to 94.3%.[1,2]Granulocyt...
关键词：anti inflammatory effects efficacy cytokine release syndrome chimeric antigen receptor T cell therapy NEUTROPENIA granulocyte colony stimulating factor 
De novo patients with high-volume metastatic hormone-sensitive prostate cancer can benefit from the addition of docetaxel to triplet therapy:Network-analysis and systematic review
《Chinese Medical Journal》2025年第2期231-233,共3页Hanxu Guo Chengqi Jin Li Ding Jun Xie Jing Xu Ruiliang Wang Hong Wang Changcheng Guo Jiansheng Zhang Bo Peng Xudong Yao Jing Yuan Bin Yang 
funded by grants from the Shanghai Science Committee Foundation(No.19411967700);the National Natural Science Foundation of China(No.31570993);the Wu Jieping Medical Foundation(No.320.6750.2020-14-7).
To the Editor:In recent years,the treatment for metastatic hormone-sensitive prostate cancer(mHSPC)has undergone rapid developments.Docetaxel(DOC)or androgen receptor-targeted agent(ARTA)and androgen deprivation thera...
关键词：triplet therapy network meta analysis DOCETAXEL androgen deprivation therapy adt systemic therapiesmultiple overall survival progression free survival 
Factors affects the implementation of active surveillance therapy for low-risk papillary thyroid microcarcinoma
《Chinese Medical Journal》2024年第15期1888-1890,共3页Xueqi Zhang Renaguli Aihaiti Weiping Teng Xiaoguang Shi 
supported by grants from the Research Fund for Public Welfare,National Health and Family Planning Commission of China(No.201402005);the Clinical Research Fund of Chinese Medical Association(No.15010010589).
To the Editor:Since the 1990s,the incidence of thyroid cancer(TC),especially papillary thyroid cancer(PTC),has increased significantly,while the mortality rate of PTC patients has been stable.Studies have confirmed th...
关键词：PAPILLARY NEEDLE diagnosis 
Dawn of CAR-T cell therapy in autoimmune diseases
《Chinese Medical Journal》2024年第10期1140-1150,共11页Yuxin Liu Minghao Dong Yunhui Chu Luoqi Zhou Yunfan You Xiaowei Pang Sheng Yang Luyang Zhang Lian Chen Lifang Zhu Jun Xiao Wei Wang Chuan Qin Daishi Tian 
Ministry of Science and Technology China Brain Initiative Grant STI2030-Major Projects(No.2022ZD0204700);National Natural Science Foundation of China(Nos.82371404,82271341,82071380,and 81873743);Knowledge Innovation Program of Wuhan Shuguang Project(No.2022020801020454)
Chimeric antigen receptor(CAR)-T cell therapy has achieved remarkable success in the treatment of hematological malignancies.Based on the immunomodulatory capability of CAR-T cells,efforts have turned toward exploring...
关键词：CAR-T cell therapy Autoimmune disease IMMUNOTHERAPY Multiple sclerosis Neuromyelitis optica spectrum disorder Systemic lupus erythematosus 
Role of ferroptosis in fibrosis:From mechanism to potential therapy
《Chinese Medical Journal》2024年第7期806-817,共12页Xuemeng Qiu Qing Bi Jiyue Wu Zejia Sun Wei Wang 
National Natural Science Foundation of China(No.82070764);Beijing Natural Science Foundation(No.7212040)
Fibrosis,which is a manifestation of the physiological response to injury characterized by excessive accumulation of extracellular matrix components,is a ubiquitous outcome of the repair process.However,in cases of re...
关键词：Ferroptosis FIBROSIS Anti-fibrotic Iron metabolism NECROINFLAMMATION Epithelial-mesenchymal transition 
Recent advances and remaining challenges in lung cancer therapy
《Chinese Medical Journal》2024年第5期533-546,共14页Tasha Barr Shoubao Ma Zhixin Li Jianhua Yu 
Lung cancer remains the most common cause of cancer death.Given the continued research into new drugs and combination therapies,outcomes in lung cancer have been improved,and clinical benefits have been expanded to a ...
关键词：Lung cancer THERAPY IMMUNOTHERAPY Combination therapy Adoptive T cell therapies 
Current assessment and management of measurable residual disease in patients with acute lymphoblastic leukemia in the setting of CAR-T-cell therapy
《Chinese Medical Journal》2024年第2期140-151,共12页Minghao Lin Xiaosu Zhao Yingjun Chang Xiangyu Zhao 
supported by grants from National Natural Science Foundation of China(Nos.81870140 and 82070184);Peking University People’s Hospital Research and Development Funds(No.RDL2021-01);Beijing Nova Program(No.20220484235);Beijing Life Oasis Public Service Center(No.CARTFR-01)
Chimeric antigen receptor(CAR)-modified T-cell therapy has achieved remarkable success in the treatment of acute lymphoblastic leukemia(ALL).Measurable/minimal residual disease(MRD)monitoring plays a significant role ...
关键词：Measurable/minimal residual disease Acute lymphoblastic leukemia Chimeric antigen receptor-modified T-cell therapy Allogeneic hematopoietic stem cell transplantation RELAPSE 
Targeting the HIV reservoir:chimeric antigen receptor therapy for HIV cure
《Chinese Medical Journal》2023年第22期2658-2667,共10页Shuang Li Hu Wang Na Guo Bin Su Olivier Lambotte Tong Zhang 
supported by grants from the National Key R&D Program of China(Nos.2021YFC2301900 and 2021YFC2301905);the National Natural Science Foundation of China(Nos.NSFC,81974303 and 82072271);Beijing Natural Science Foundation(Nos.L222068 and Z220018);the High-Level Public Health Specialized Talents Project of Beijing Municipal Health Commission(Nos.2022-2-018 and 2022-1-007);the Climbing the peak(Dengfeng)Talent Training Program of Beijing Hospitals Authority(Nos.DFL20191701);the Beijing Health Technologies Promotion Program(BHTPP202002)and Beijing Key Laboratory for HIV/AIDS Research(No.BZ0089).
Although antiretroviral therapy(ART)can reduce the viral load in the plasma to undetectable levels in human immunodeficiency virus(HIV)-infected individuals,ART alone cannot completely eliminate HIV due to its integra...
关键词：Functional HIV cure HIV reservoir Chimeric antigen receptor therapy CAR T cells CAR natural killer cells 
全选清除导出
共16页<12345678910>
检索报告 对象比较 聚类工具 使用帮助 返回顶部